Patent intelligence · US
US 10954530
Retroviral and lentiviral vectors
Retroviral and lentiviral vectors
Patent details — US 10954530
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 23, 2021
- Expiration
- Mar 18, 2041
- Applicant
- AUTOLUS LIMITED
- Claims
- 12
- CPC classes
- A61K, A61K2039/507, A61K35/76, A61K38/00
Quick answer
US 10954530 (Retroviral and lentiviral vectors) is held by AUTOLUS LIMITED. Status: granted. Granted Mar 23, 2021. Expires Mar 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AUTOLUS LIMITED
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2039/507, A61K35/76, A61K38/00
More from AUTOLUS LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12398194
Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface
granted -
US 12325733
Binding domain
granted -
US 12304942
Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor
granted -
US 12269860
Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR
granted -
US 12241068
CD79-specific chimeric antigen receptor
granted -
US 12234295
Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof
granted -
US 12187769
Cell
granted -
US 12049510
Chimeric antigen receptor
granted
Frequently asked questions
What is US patent 10954530?
US 10954530 (Retroviral and lentiviral vectors) is held by AUTOLUS LIMITED. Status: granted. Granted Mar 23, 2021. Expires Mar 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10954530?
AUTOLUS LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 49 pharmaceutical patents for this assignee.
When does US 10954530 expire?
Our index shows an expiration date of Mar 18, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.